Show results for
Refine by
Therapeutic Antibody Suppliers Serving Estonia
32 companies found
based inRedcar, UNITED KINGDOM
Absolute Antibody was founded in 2012 with a vision to make engineered recombinant antibodies accessible to all, and we remain the only company 100% focused on recombinant antibody technology. Though recombinant antibodies are standard in the ...
Polyclonal antibodies are widely used reagents across research and diagnostics. They are generated by immunizing animals with an immunogen and harvesting the animals’ blood to obtain immunoreactive serum. While polyclonal antibodies offer a ...
based in
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced merger with AVROBIO, Inc. The combined company will ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Deliver potent cell-killing compounds specifically to diseased target cells with optimal safety and efficacy. ZymeLink™, a next-generation antibody drug conjugate (ADC) platform, is a suite of proprietary cytotoxins ...
based inMumbai, INDIA
Krishgen BioSystems (Krishgen) is privately-owned biotech firm with academic linkages to provide tools to scientists. With the strong background in immunology, we believe in the delivering quality kits, reagents and consumables. Certified and ...
Adalimumab biosimilar is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF), was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and ...
based inRochester Hills, MICHIGAN (USA)
Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company’s primary focus is on the identification and assay of biomarkers for ...
based inHertfordshire, UNITED KINGDOM
Fluidic Sciences Ltd specializes in microfluidic technologies for accelerating protein interaction analysis and single-cell screening. Their flagship product, Fluidity One-M, enables rapid measurements of binding affinity, concentration, ...
Fluidic Sciences Ltd. offers the Fluidity One-M instrument, integrated with Microfluidic Diffusional Sizing (MDS) technology, specifically engineered for in-solution analysis of antibodies and their targets throughout various stages ...
based inYokohama, JAPAN
MabGenesis Inc. is a biopharmaceutical startup that uses 30+ years of antibody research to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and animals. We have the world’s highest quality antibody libraries ...
based inLebanon, NEW HAMPSHIRE (USA)
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging diseases. We are a recognized leader with a rich stable of discoveries, developed in concert with premiere ...
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging ...
based inBasel, SWITZERLAND
Granite Bio is at the forefront of biotechnological innovation, concentrating on the treatment of chronic inflammatory, autoimmune, and fibrotic diseases. These conditions are prevalent as they lack effective therapeutic options, resulting in ...
Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Antibody discovery is challenging. Only 5 of every 5000 concepts make it into the clinic.1 Many antibody failures can be attributed to a lack of specificity for disease-causing cells versus healthy cells and a lack of efficacy – both ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like ...
based inMadison, WISCONSIN (USA)
Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ...
based inDuisburg, GERMANY
Genekam Biotechnology AG was found in 1999. It started offering DNA-Tests in 2001. From 2004, it started development of PCR kits while exporting to 5 countries, today (2015) it exports to 70 countries in the world. Genekam covers different targets ...
based inSeattle, WASHINGTON (USA)
window into the adaptive immune system the world hadn’t thought possible. Together, Harlan and his brother Chad, founded Adaptive to meet the worldwide demand for immunosequencing technology. Over the past decade, we have developed our proprietary ...
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous ...
based inBerlin, GERMANY
The BioTeZ Berlin-Buch GmbH is a Biotechnology company founded in 1992. BioTeZ is partner of research institutions, the pharmaceutical industry and laboratory diagnostics. Our sister company Steffens-Biotec, Ebringen (ISO 13485) is specialised in ...
based inOklahoma City, OKLAHOMA (USA)
Cytovance Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
Anti-Idiotype Ankyrons a game-changer for developing assays to track target-specific antibodies. Take the pain out of targeting the idiotype of your antibodies. Detecting and targeting specific antibody idiotypes is key for developing effective ...
based inProvidence, RHODE ISLAND (USA)
Ocean Biomedical is a 21st century biopharma company that partners with leading scientists and research institutions to accelerate the translation of new discoveries into breakthrough medicines. We're working to bring together the interdisciplinary ...
New therapeutic antibodies for effective treatment of NSCLC and other disorders. We are moving towards Phase 1 clinical trials of patented antibodies for the treatment of NSCLC. Our lead program, ...
